


addition of claims 12-24. Claims 1 and 12-24 are in the application. Support for the foregoing amendment may be found in throughout the specification, the examples and the claims as originally filed. A clean copy of the claims is attached hereto.

The specification is being amended to identify the related parent application of which this application is a continuation.

Respectfully submitted,

Dated: 12-19-00

  
\_\_\_\_\_  
John A. Dhuey  
Registration Number 26,265  
Attorney for the Applicants

**ALZA Corporation**  
1900 Charleston Road  
P.O. Box 7210  
Mountain View, CA 94039-7210  
650-564-5699

[illegible]

**CLAIMS:**

1. A process for providing a dosage form, wherein the process comprises the steps as follows:

(a) blending an osmotic hydrogel and an osmotically effective solute to provide a composition that increases in volume in the presence of an aqueous fluid;

(b) blending a hydroxyalkylcellulose and water to provide a granulation solution;

(c) spraying the granulation solution (b) onto the composition provided in (a) to provide granules;

(d) blending a drug, a surfactant, and a member selected from the group consisting of a mono- and di-glyceride to provide a drug formulation;

(e) adding the drug formulation (d) to a capsule;

(f) adding the sprayed composition of (c) to the capsule;

(g) coating the capsule with a semipermeable composition to provide a membrane permeable to an aqueous fluid; and,

(h) providing an exit in the membrane (g) for delivering the drug at a sustained-release and controlled rate over an extended time from the dosage form.

12. A sustained-release, liquid formulation dosage form comprising a capsule comprising an expandable layer which expands upon contact with fluid; and a liquid, drug layer consisting essentially of a drug, a surfactant, and a member selected from the group consisting of a mono- and di-glyceride.

13. The dosage form of claim 12 wherein the expandable layer comprises an osmotic hydrogel, an osmotically effective solute, and a hydroxyalkylcellulose.

14. The dosage form of claim 13 comprising a semipermeable membrane surrounding the capsule and having an exit orifice formed or formable therein.

15. The dosage form of claim 14 wherein the membrane comprises a cellulose acetate and a polyethylene glycol.

16. The dosage form of claim 14 wherein the drug is selected from the group consisting of a peptide, protein, protein anabolic hormone, growth promoting hormone, endocrine system hormone, porcine growth promoting hormone, bovine growth promoting hormone, equine growth promoting hormone, human growth promoting hormone, hormone derived from a pituitary gland, hormone derived from a hypothalamus gland, recombinant DNA, somatotropin, gonadotropic releasing hormone, follicle stimulating hormone, luteinizing hormone, LH-RH, insulin, colchicine, chorionic gonadotropin, oxytocin, vasopressin, desmopressin, adrenocorticotrophic hormone, prolactin, bupressin, thyroid stimulating hormone, secretin, pancreozymin, enkephalin and glucagon.

17. The dosage form of claim 14 wherein the surfactant is selected from the group consisting of polyoxyethylenated castor oil comprising 9 moles to 52 moles of ethylene oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 4 moles of ethylene oxide, polyoxyethylenated sorbitan tristearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan trioleate comprising 20 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 8 moles of ethylene oxide, polyoxyethylene lauryl ether, polyoxyethylenated stearic acid comprising 40 moles to 50 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 50 moles of ethylene oxide, polyoxyethylenated stearyl alcohol comprising 2 moles of ethylene oxide, and polyoxyethylenated oleyl alcohol comprising 2 moles of ethylene oxide.

18. A sustained-release, liquid formulation dosage form comprising a capsule comprising an expandable layer which expands upon contact with fluid; and a liquid,

23. The dosage form of claim 20 wherein the surfactant is selected from the group consisting of polyoxyethylenated castor oil comprising 9 moles to 52 moles of ethylene oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 mules of

[illegible]

24. The dosage form of claim 20 wherein the membrane comprises a thermoplastic polymer composition having a softening point of 40°C to 180°C.